SHAREHOLDER ALERT: Weiss Law Investigates IMARA Inc.

NEW YORK, Oct. 14, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of IMARA Inc. ("IMARA" or the "Company") (NASDAQ: IMRA) in connection with the proposed merger of the Company with Enliven Therapeutics, Inc. ("Enliven"). Under the terms of the merger agreement, IMARA will issue IMARA common stock as merger consideration in exchange for the cancellation of shares of capital stock of Enliven and Enliven will become a wholly owned subsidiary of IMARA. Upon completion of the transaction, IMARA shareholders are expected to own only approximately 16% of the combined company, while Enliven shareholders are expected to own approximately 84% of the combined company. 

If you own IMARA shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:

https://www.weisslaw.co/news-and-cases/imra 
Or please contact:
Joshua Rubin, Esq.
Weiss Law
305 Broadway, 7^th Floor
New York, NY  10007
(212) 682-3025
(888) 593-4771
[email protected]

Weiss Law is investigating whether (i) IMARA's board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the minority equity interest in the combined company under the proposed transaction is fair to IMARA's shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed. 

Weiss Law has litigated hundreds of stockholder class and derivative actions for violation corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [email protected]

SOURCE Weiss Law

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED